Reduction in skin microvascular density and changes in vessel morphology in patients treated with sunitinib

No abstract is available for this paper.

• Publication year

  2010

• Venue

  Anti-Cancer Drugs

• Publication date

  2010-04-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1097/CAD.0b013e3283359c79PMID 20051825
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Tumor angiogenesis

  2020cited by this paper
• Cardiotoxicity Associated with the Tyrosine Kinase Inhibitor Sunitinib

  2013cited by this paper
• Vascular Endothelial Growth Factor Receptor 2 Controls Blood Pressure by Regulating Nitric Oxide Synthase Expression

  2009cited by this paper
• Sunitinib-induced hemoglobin changes are related to the dosing schedule.

  2009cited by this paper
• Phase I trial of bevacizumab plus escalated doses of sunitinib in patients with metastatic renal cell carcinoma.

  2009cited by this paper
• Increased numbers of small circulating endothelial cells in renal cell cancer patients treated with sunitinib

  2009cited by this paper
• Arterial hypertension correlates with clinical outcome in colorectal cancer patients treated with first-line bevacizumab.

  2009cited by this paper
• Risk of hypertension and renal dysfunction with an angiogenesis inhibitor sunitinib: Systematic review and meta-analysis

  2009cited by this paper
• Arterial hypertension and clinical benefit of sunitinib, sorafenib and bevacizumab in first and second-line treatment of metastatic renal cell cancer.

  2009cited by this paper
• Predictive factors for severe toxicity of sunitinib in unselected patients with advanced renal cell cancer

  2009cited by this paper
• DERMATOLOGICAL MANIFESTATIONS OF VENOUS DISEASE . PART II : RETICULATE ERUPTIONS

  2008cited by this paper
• Hypertension and Rarefaction during Treatment with Telatinib, a Small Molecule Angiogenesis Inhibitor

  2008cited by this paper
• Hypertension and clinical benefit of bevacizumab in the treatment of advanced renal cell carcinoma.

  2008cited by this paper
• Blood pressure rise following angiogenesis inhibition by bevacizumab. A crucial role for microcirculation.

  2008cited by this paper
• Blood pressure as a potential biomarker of the efficacy angiogenesis inhibitor.

  2008cited by this paper
• Tumor angiogenesis.

  2008cited by this paper
• Home blood-pressure monitoring in patients receiving sunitinib.

  2008cited by this paper
• Predictive factors for severe toxicity of sunitinib in unselected patients with advanced renal cell cancer

  2008cited by this paper
• Hypertension as a predictive factor of Sunitinib activity.

  2007cited by this paper
• Microvascular function: a potential link between salt sensitivity, insulin resistance and hypertension

  2007cited by this paper
• Microvascular dysfunction: a potential pathophysiological role in the metabolic syndrome.

  2007cited by this paper
• Mechanisms of hypertension associated with BAY 43-9006.

  2006cited by this paper
• Angiogenesis inhibitors and hypertension: an emerging issue.

  2006cited by this paper
• Livedo reticularis: an update.

  2005cited by this paper
• Direct evidence for insulin-induced capillary recruitment in skin of healthy subjects during physiological hyperinsulinemia.

  2002cited by this paper
• Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma.

  2002cited by this paper
• Impaired Skin Capillary Recruitment in Essential Hypertension Is Caused by Both Functional and Structural Capillary Rarefaction

  2001cited by this paper
• [New guidelines to evaluate the response to treatment in solid tumors].

  2000cited by this paper
• New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada.

  2000cited by this paper
• Microvascular function relates to insulin sensitivity and blood pressure in normal subjects.

  1999cited by this paper
• Studies with iontophoretic administration of drugs to human dermal vessels in vivo: cholinergic vasodilatation is mediated by dilator prostanoids rather than nitric oxide.

  1998cited by this paper
• Quantitative nailfold capillaroscopy findings in a population with connective tissue disease and in normal healthy controls.

  1996cited by this paper
• Microvascular rarefaction and tissue vascular resistance in hypertension.

  1989cited by this paper

• Renal-vascular axis: unmasking its role in vascular endothelial growth factor-inhibitor vascular toxicity in cancer patients.

  2026cites this paper
• Translational regulation of SND1 governs endothelial homeostasis during stress

  2025cites this paper
• The nephrotoxic effects of anti-cancer therapies: consensus report of the 34th Acute Disease Quality Initiative workgroup.

  2025cites this paper
• Hypertension toxicity of VEGFR-TKIs in cancer treatment: incidence, mechanisms, and management strategies

  2024cites this paper
• Comparison of Changes in Retinal Vascular Parameters and Density in Patients with Moyamoya Disease: A Retrospective Study

  2024cites this paper
• Assessment of plasma levels of D-dimer and lipid profile in women with breast cancer on chemotherapy at Nnamdi Azikiwe university teaching hospital, Nnewi

  2024cites this paper
• Modulation of lncRNA links endothelial glycocalyx to vascular dysfunction of tyrosine kinase inhibitor.

  2023cites this paper
• The importance of microvascular inflammation in ageing and age-related diseases: a position paper from the ESH working group on small arteries, section of microvascular inflammation

  2023cites this paper
• Cardiotoxicity of Selected Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients with Renal Cell Carcinoma

  2023cites this paper
• Cancer Therapy-Related Hypertension: A Scientific Statement From the American Heart Association.

  2023cites this paper
• Apatinib for recurrent/progressive glioblastoma multiforme: A salvage option

  2022cites this paper
• Hypoxia signaling and oxygen metabolism in cardio-oncology.

  2021cites this paper
• Cardiotoxic effects of angiogenesis inhibitors

  2021cites this paper
• Cardiovascular Effects of Anti-angiogenic Drugs

  2020cites this paper
• Hypertension and Heart Failure: Epidemiology, Mechanisms and Treatment

  2020cites this paper
• Vascular effect of bevacizumab: is it too early to draw conclusions?

  2020cites this paper
• Acute coronary syndrome in cancer patients. Part I: pathophysiology, clinical presentation and diagnosis

  2020cites this paper
• Is there truly an increase in risk of cardiovascular and hematological adverse events with vascular endothelial growth factor receptor tyrosine kinase inhibitors?

  2019cites this paper
• Tyrosine Kinase Inhibitor-Induced Hypertension: Role of Hypertension as a Biomarker in Cancer Treatment.

  2019cites this paper
• The Patients’ Journey with Targeted Therapies

  2019cites this paper
• Longitudinal Assessment of Vascular Function With Sunitinib in Patients With Metastatic Renal Cell Carcinoma

  2018cites this paper
• Clinical Manual for Diagnosis, Prevention and Treatment of Cardiovascular Complications of Cancer Therapy. Part I

  2018cites this paper
• Toxicity of cancer therapy: what the cardiologist needs to know about angiogenesis inhibitors

  2018cites this paper
• Acute and chronic effects of anti-cancer agents on cardiac mitochondrial function

  2017cites this paper
• Early Actions of Anti-Vascular Endothelial Growth Factor/Vascular Endothelial Growth Factor Receptor Drugs on Angiogenic Blood Vessels.

  2017cites this paper
• Capillary rarefaction from the kidney point of view

  2017cites this paper
• An exploratory association of polymorphisms in angiogenesis-related genes with susceptibility, clinical response and toxicity in gastrointestinal stromal tumors receiving sunitinib after imatinib failure

  2017cites this paper
• Recent Advances in Hypertension and Cardiovascular Toxicities With Vascular Endothelial Growth Factor Inhibition

  2017influential citation
• A phase 2 study of the efficacy and biomarker on the combination of transarterial chemoembolization and axitinib in the treatment of inoperable hepatocellular carcinoma

  2017cites this paper
• Survival of encapsulated islets: More than a membrane story.

  2016cites this paper
• Influence of Tyrosine Kinase Inhibitors on Hypertension and Nephrotoxicity in Metastatic Renal Cell Cancer Patients

  2016cites this paper
• Vascular Toxicities of Cancer Therapies: The Old and the New – An Evolving Avenue

  2016cites this paper
• Mechanisms of Hypertension and Renal Injury During Vascular Endothelial Growth Factor Signaling Inhibition

  2016cites this paper
• Molecular mechanisms for vascular complications of targeted cancer therapies.

  2016cites this paper
• Influence of Adjuvant Therapy in Cancer Survivors on Endothelial Function and Skeletal Muscle Deoxygenation

  2016cites this paper
• Hypertension and renal toxicity during angiogenesis inhibition : Salt dependency and treatment options

  2016cites this paper
• Chapter 10 – Cardiovascular Complications from Cancer Therapy: Hypertension–Focus on Vascular Endothelial Growth Factor Inhibitors

  2016cites this paper
• Vascular Toxicities of Cancer Therapies

  2016cites this paper
• Hypertension in cancer patients treated with anti-angiogenic based regimens

  2015cites this paper
• The skin microcirculatory changes in the normal and hypertensive elderly

  2015cites this paper
• Treatment of sunitinib-induced hypertension in solid tumor by nitric oxide donors☆

  2015cites this paper
• Neovascularization of the atherosclerotic plaque: interplay between atherosclerotic lesion, adventitia-derived microvessels and perivascular fat

  2015cites this paper
• Etiology of angiogenesis inhibition-related hypertension.

  2015cites this paper
• Functional and structural abnormalities of the skin microcirculation in hemodialysis patients

  2014cites this paper
• Arterial hypertension induced by angiogenesis inhibitors

  2014cites this paper
• Targeting the epidermal growth factor receptor in solid tumors: focus on safety

  2014cites this paper
• Tyrosine Kinase Inhibitors Induced Thyroid Dysfunction: A Review of Its Incidence, Pathophysiology, Clinical Relevance, and Treatment

  2013cites this paper
• Dermatitis and Alopecia

  2013cites this paper
• Impaired coronary flow reserve in metastatic cancer patients treated with sunitinib.

  2013cites this paper
• Multiple Roles of Proteases in Angiogenesis

  2013cites this paper
• Pathobiology of Cancer Regimen-Related Toxicities

  2013cites this paper
• Reduction in Thyroid Perfusion After Bevacizumab Treatment

  2013cites this paper
• Mechanism of hypertension and proteinuria during angiogenesis inhibition: evolving role of endothelin-1

  2013cites this paper
• Sunitinib for advanced renal cell cancer : Clinical and pharmacodynamic aspects

  2012cites this paper
• Sunitinib-Induced Systemic Vasoconstriction in Swine Is Endothelin Mediated and Does Not Involve Nitric Oxide or Oxidative Stress

  2012cites this paper
• Sunitinib‐induced changes in circulating endothelial cell‐related proteins in patients with metastatic renal cell cancer

  2012cites this paper
• The risk of hand foot skin reaction to pazopanib, a novel multikinase inhibitor: a systematic review of literature and meta-analysis

  2012cites this paper
• Predictive Factors of Efficacy of Sunitinib Therapy in Gastrointestinal Stromal Tumours

  2012cites this paper
• The outcome and predictive factors of sunitinib therapy in advanced gastrointestinal stromal tumors (GIST) after imatinib failure - one institution study

  2012cites this paper
• Polymorphisms in Endothelial Nitric Oxide Synthase (eNOS) and Vascular Endothelial Growth Factor (VEGF) Predict Sunitinib‐Induced Hypertension

  2012cites this paper
• Management of treatment-associated toxicites of anti-angiogenic therapy in patients with brain tumors.

  2012cites this paper
• Hypertension induced by antiangiogenic therapy: clinical and pathophysiological aspects

  2012cites this paper
• Capillary rarefaction in advanced chronic kidney disease is associated with high phosphorus and bicarbonate levels.

  2011cites this paper
• Toxicity as a biomarker of efficacy of molecular targeted therapies: focus on EGFR and VEGF inhibiting anticancer drugs.

  2011cites this paper
• Hypertension as a Biomarker of Efficacy in Patients With Metastatic Renal Cell Carcinoma Treated With Sunitinib

  2011cites this paper
• Re: Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib.

  2011cites this paper
• Cardiovascular, renal and thyroid toxicity during angiogenesis inhibition: A translational approach

  2011cites this paper
• Targeted therapy for renal cell cancer: current perspectives.

  2010cites this paper
• Targeted therapies in renal cell cancer: recent developments in imaging

  2010cites this paper
• Sunitinib-induced reduction in skin microvascular density is a reversible phenomenon.

  2010cites this paper
• Antitumour and immune-adjuvant activities of protein-tyrosine kinase inhibitors.

  2010cites this paper